- Life Sciences
Tecan Group Full Year 2022 Earnings: Revenues Beat Expectations, EPS Lags
Tecan Group (VTX:TECN) Full Year 2022 Results
Key Financial Results
- Revenue: CHF1.14b (up 21% from FY 2021).
- Net income: CHF121.1m (flat on FY 2021).
- Profit margin: 11% (down from 13% in FY 2021). The decrease in margin was driven by higher expenses.
- EPS: CHF9.53 (down from CHF9.95 in FY 2021).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Tecan Group Revenues Beat Expectations, EPS Falls Short
Revenue exceeded analyst estimates by 1.8%. Earnings per share (EPS) missed analyst estimates by 9.0%.
Looking ahead, revenue is forecast to grow 5.8% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Life Sciences industry in Switzerland.
Performance of the Swiss Life Sciences industry.
The company's shares are down 1.3% from a week ago.
Balance Sheet Analysis
While it's very important to consider the profit and loss statement, you can also learn a lot about a company by looking at its balance sheet. We've done some analysis and you can see our take on Tecan Group's balance sheet.
Valuation is complex, but we're helping make it simple.
Find out whether Tecan Group is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.View the Free Analysis
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Tecan Group AG provides laboratory instruments and solutions for pharmaceutical, biotechnology and in-vitro diagnostic companies, university research departments, and diagnostic and other laboratories.
Excellent balance sheet with moderate growth potential.